Wealthcare Advisory Partners Boosts Amgen Stake by 77.7%

The investment firm increased its holdings in the biotech giant during Q4 2025.

Mar. 29, 2026 at 11:13am

Got story updates? Submit your updates here. ›

Wealthcare Advisory Partners LLC, an institutional investor, significantly increased its position in Amgen Inc. (NASDAQ: AMGN) during the fourth quarter of 2025, acquiring an additional 9,696 shares to bring its total holdings to 22,181 shares worth $7.26 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a diverse portfolio of innovative medicines. Institutional investors closely monitor Amgen's stock performance and ownership changes, as they can signal broader market trends and investor sentiment around the company's future prospects.

The details

According to a recent SEC filing, Wealthcare Advisory Partners LLC increased its stake in Amgen by 77.7% during the fourth quarter of 2025. The firm now owns 22,181 shares of the medical research company's stock, up from 12,485 shares held at the end of the prior quarter.

  • Wealthcare Advisory Partners LLC filed its Q4 2025 holdings report with the SEC on March 29, 2026.

The players

Wealthcare Advisory Partners LLC

An institutional investment firm that manages assets for clients.

Amgen Inc.

A global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Amgen's stock has been a focus for institutional investors, with Wealthcare Advisory Partners' significant increase in its position signaling confidence in the biotech company's long-term growth prospects. As Amgen continues to advance its pipeline of innovative medicines, its stock performance and ownership changes will remain closely watched by the investment community.